| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/16/2012 | US20120039841 T-Helper Cell Type 17 Lineage-Specific Adjuvants, Compositions and Methods |
| 02/16/2012 | US20120039840 Use of IL-27-P28 to antagonize IL-6 mediated signaling |
| 02/16/2012 | US20120039825 Phototherapy compositions and methods |
| 02/16/2012 | US20120039810 Aptamer-containing compositions and methods for targeting e-selectin |
| 02/16/2012 | US20120039808 Brain Tumor Stem Cell Differentiation Promoter, and Therapeutic Agent for Brain Tumor |
| 02/16/2012 | US20120039807 Anti-Tenascin-C A2 Antibodies and Methods of Use |
| 02/16/2012 | US20120039806 Compounds and Methods for Modulating an Immune Response |
| 02/16/2012 | US20120039805 Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample |
| 02/16/2012 | US20120039804 Novel Tricyclic Modulators of Cannabinoid Receptors |
| 02/16/2012 | US20120039802 Peptides that specifically bind hgf receptor (cmet) and uses thereof |
| 02/16/2012 | US20120039801 SPARC binding peptides and uses thereof |
| 02/16/2012 | US20120039800 Platinum Acridine Anti-Cancer Compounds And Methods Thereof |
| 02/16/2012 | US20120039799 Viral nanoparticle cell-targeted delivery platform |
| 02/16/2012 | US20120039798 Methods of modifying p53 acetylation and treating cancer using avra |
| 02/16/2012 | US20120039797 Antibody Therapy |
| 02/16/2012 | US20120039796 Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients |
| 02/16/2012 | US20120038073 Spray drying methods and related compositions |
| 02/16/2012 | CA2848342A1 Acylsulfonamides and processes for producing the same |
| 02/16/2012 | CA2808435A1 Heterocyclic compound |
| 02/16/2012 | CA2807971A1 Heteroaryls and uses thereof |
| 02/16/2012 | CA2807944A1 Improved hematopoietic stem and progenitor cell therapy |
| 02/16/2012 | CA2807942A1 Erythrocyte-binding therapeutics |
| 02/16/2012 | CA2807685A1 Peptidomimetic macrocycles |
| 02/16/2012 | CA2807616A1 Methods and compositions for preventing a condition |
| 02/16/2012 | CA2807484A1 Methods for extending progression-free survival using 10-propargyl-10-deazaaminopterin |
| 02/16/2012 | CA2807359A1 Inhibitor of casein kinase 1.delta. and casein kinase 1.epsilon. |
| 02/16/2012 | CA2807051A1 Besylate salt of a btk inhibitor |
| 02/16/2012 | CA2806614A1 Combinatory cancer treatment |
| 02/16/2012 | CA2806447A1 Neuropilin as a biomarker for bevacizumab combination therapies |
| 02/16/2012 | CA2806324A1 Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof |
| 02/15/2012 | EP2418223A2 Single-chain multivalent binding proteins with effector function |
| 02/15/2012 | EP2418222A1 Therapeutic agent for diseases in which neoplastic proliferation of plasma cells occurs |
| 02/15/2012 | EP2418219A1 Methods and agents for the treatment of cancer |
| 02/15/2012 | EP2418212A1 Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 02/15/2012 | EP2418210A1 Thiophene-carboxamides useful as inhibitors of protein kinases |
| 02/15/2012 | EP2418209A1 Aurora kinase modulators and method of use |
| 02/15/2012 | EP2418206A2 Benzodiazepine derivatives useful in the treatment of autoimmune disorders |
| 02/15/2012 | EP2418205A1 Pyrimidine urea derivatives as kinase inhibitors |
| 02/15/2012 | EP2418196A1 Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors |
| 02/15/2012 | EP2417984A1 Method for treatment of blood tumor using anti-tim-3 antibody |
| 02/15/2012 | EP2417975A1 Fulvestrant nanosphere/microsphere and preparative method and use thereof |
| 02/15/2012 | EP2417974A1 Combination therapy for treatment of immune disorders |
| 02/15/2012 | EP2417943A1 Drug-delivery endovascular stent and method for treating restenosis |
| 02/15/2012 | EP2417160A1 Bispecific anti-erbb-1/anti-c-met antibodies |
| 02/15/2012 | EP2417146A1 (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer |
| 02/15/2012 | EP2417138A1 Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
| 02/15/2012 | EP2417136A1 Imidaz0ý1,2-a¨pyridine-6-carboxamide derivatives, their use for the treatment of colon cancer and their method of manufacture |
| 02/15/2012 | EP2417127A1 Kinase inhibitors and method of treating cancer with same |
| 02/15/2012 | EP2417125A1 N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as mps1 kinase inhibitors |
| 02/15/2012 | EP2417123A2 Therapeutic compositions and related methods of use |
| 02/15/2012 | EP2417120A1 Substituted piperidines as ccr3 antagonists |
| 02/15/2012 | EP2416805A1 Amatoxin-armed target-binding moieties for the treatment of cancer |
| 02/15/2012 | EP2416804A2 Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
| 02/15/2012 | EP2416788A2 Coupled identification and treatment of cancer |
| 02/15/2012 | EP2416781A1 Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
| 02/15/2012 | EP2416780A1 Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
| 02/15/2012 | EP2416774A1 Treatment regimen utilizing neratinib for breast cancer |
| 02/15/2012 | EP2416773A1 Checkpoint kinase 1 inhibitors for potentiating dna damaging agents |
| 02/15/2012 | EP2416657A1 Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof |
| 02/15/2012 | EP2124944B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors |
| 02/15/2012 | EP2073806B1 Use of spiro-oxindole compounds as therapeutic agents |
| 02/15/2012 | EP2027107B1 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors |
| 02/15/2012 | EP1971680B1 Method for generating dendritic cells employing decreased temperature |
| 02/15/2012 | EP1951891B1 Cancer antigen mage-a9 and uses thereof |
| 02/15/2012 | EP1831199B1 MMP inhibitors |
| 02/15/2012 | EP1797077B1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i |
| 02/15/2012 | EP1781255B1 Compositions and methods for treating leukemia |
| 02/15/2012 | EP1648506B1 Method for treating synovial sarcoma |
| 02/15/2012 | EP1532161B1 Vectors for expression of hml-2 polypeptides |
| 02/15/2012 | EP1488795B1 Remedies for lung cancer |
| 02/15/2012 | EP1395595B1 Tetramerous derivative of indole-3-carbinol with anti-carcinogenic activity and method of synthesis of said derivative |
| 02/15/2012 | EP1381432B1 HSA-free formulations of interferon-beta |
| 02/15/2012 | EP1328293B1 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| 02/15/2012 | EP1309705B1 Multivalent target binding protein |
| 02/15/2012 | CN1942472B 回折拟态及其相关方法 Mimicry and related methods folded back |
| 02/15/2012 | CN1929862B 拮抗性抗-cd40单克隆抗体治疗慢性淋巴细胞性白血病的应用 Monoclonal antibody antagonist anti -cd40 application to treat chronic lymphocytic leukemia |
| 02/15/2012 | CN1536069B 大规模生产虫草菌和灵芝菌的方法 Mass production of Cordyceps and Ganoderma lucidum methods |
| 02/15/2012 | CN102356155A Neil3 peptides and vaccines including the same |
| 02/15/2012 | CN102356085A Imidazothiazole derivative having proline ring structure |
| 02/15/2012 | CN102356083A Use of kinase inhibitor for treatment of thymoma |
| 02/15/2012 | CN102356082A 3, 3' -spiroindolinone derivatives as anticancer agents |
| 02/15/2012 | CN102355908A Nanoparticle formulated glycolipid antigens for immunotherapy |
| 02/15/2012 | CN102355897A Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug |
| 02/15/2012 | CN102352368A ING4 and OSM double-gene co-expression vector and application thereof |
| 02/15/2012 | CN102352356A Bcl11a siRNA-2292 restraining expression of BCL11A and proliferation of tumorous B cells and application thereof |
| 02/15/2012 | CN102352344A Peripheral blood mononuclear cell enrichment method |
| 02/15/2012 | CN102352342A Method for amplifying cytokine induced kill cells (CIK) and CIK cell preparation |
| 02/15/2012 | CN102351952A Low-saccharification mutant interferon lambda1 as well as expression and purification methods and application thereof |
| 02/15/2012 | CN102351937A Acetylated 18-alpha glycyrrhizic acid and preparation method thereof |
| 02/15/2012 | CN102351931A Pyrimidine nucleoside derivatives as well as synthesis method and application thereof in preparation of anti-tumor and antiviral drugs |
| 02/15/2012 | CN102351911A Method for synthesizing anticancer compound Na4Bi2Mn2W20C6H84N4O105 |
| 02/15/2012 | CN102351880A Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors |
| 02/15/2012 | CN102351870A Method for preparing benzacridine derivative and application of benzacridine derivative as anti-cancer medicine |
| 02/15/2012 | CN102351859A Antibiotic Pseudonocardian A and Pseudonocardian B, its preparation method thereof and its application in preparation of antibiotics and antitumor drug |
| 02/15/2012 | CN102351852A Coumarone compound, its preparation method and its application |
| 02/15/2012 | CN102351848A Rotenone cyclopropanecarboxamide and its preparation method and use |
| 02/15/2012 | CN102351842A F,G,H,I and K crystal forms of imatinib mesylate |
| 02/15/2012 | CN102351823A Lactucin derivative, and preparation method and application thereof |
| 02/15/2012 | CN102351769A Chiral 2,5-pyrroline derivative, and synthetic method and biological activity thereof |
| 02/15/2012 | CN102351732A Nuclear receptor binding agents |